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EPIGENETIC ANALYSES OF BEHÇET SYNDROME TWINS 
SUMMARY 
Behçet syndrome (BS) is a multisystem vasculitis characterized by skin and 
mucosa lesions and musculoskeletal, ocular, gastrointestinal, neurological 
and major vessel involvement. It is seen mainly in the Mediterranean basin, 
Middle East and the Far East. Turkey has the highest prevalence which is 8 
to 42 per10000 populations, while the frequency is lower in western 
countries. The disease is more severe among young males and the severity 
diminishes with age. The ultimate etiology of Behçet's syndrome remains 
unknown. Current evidence suggests that interplay of genetic and 
environmental factors may be responsible. Abnormal neutrophil function, 
alterations in lymphocytes, and some infectious agents are also proposed to 
play a role in Behçet syndrome. Strong association between BS and HLA-
B51 indicates the importance of genetics in the etiology of the disease. On 
the other hand, deficient concordance in monozygotic twins and sporadic 
BS in families with no disease background points out also the importance of 
environmental elements. 
Along with stochastic epigenetic changes related to age, epigenetic analyses 
in discordant monozygotic twins are considered to be able to explain the 
changes that are due to environmental factors.  
This study aimed to analyze global methylation, an important epigenetics 
mechanism of BS twins. To this end, methylation profile of 4 BS 
monozygotic (MZ) (n= 8) and 4 dizygotic (DZ) (n= 8) twins along with 
healthy controls (8 twins, n=16) were investigated; MZ twins whom one of 
them is BS and the other one is healthy (BS-healthy twins), MZ twins who 
both are BS, and DZ twins whom one of them is BS were compared with 
the MZ and DZ healthy controls. Global methylation value was obtained by 
injecting digested DNA samples to HPLC (HPLC- High Performance 
Liquid Chromatography) machine and separating nucleosides including dC 
and 5-mdC. The area below the peaks was recorded. Tests were triplicated, 
5-mdC: dC ratio for each of the samples was calculated (%RSD= 7%). The 
average values were compared between groups using student T test 
analyses.  
It was concluded that there is a smaller difference between methylation 
pattern of the twins in healthy control group compared to BS twins (P= 
0.02876). MZ BS twins versus MZ healthy controls (P= 0.04133) and DZ 
BS twins versus DZ healthy controls (P= 0.09551) were analyzed 
separately. Results showed significant relationship between MZ twins, but 
not for DZ twins based on Student T test analyses as expected. Correlation 
results showed a stronger relationship among MZ twins (ρ~ 1) compared 
with DZ twins in discordant BS twins (ρ= 0.73). 
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Main limitation of this study is the small sample size. More data is needed 
to confirm our preliminary findings. Future studies would be to examine the 
impression of methylation profile differences on gene expression. As a 
conclusion, we would be able to define the effect of environmental 
epigenetic differences on gene regions. 
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BEHÇET SENDROMLU İKİZLERİNDE EPİGENETİK ANALİZLER 
ÖZET 
Behçet sendromu deri ve mukoza kezyonları ile ayırt edilen muskuloskeletal, oküler, 
gastrointestinal, nörolojik ve bir çok ana damarları kapsayan  vücuttaki birçok doku 
ve organ sistemini etkileyebilen multisistem vaskülit bir hastalıktır. Hastalık özellikle 
Akdeniz, Orta Doğu ve Uzak Doğu bölgelerinde yaygın olarak görülmektedir. 
Türkiye’de 10bin’de 8-42 görülme sıklığı ile bu oran en yüksek iken, batı ülkelerinde 
oran düşüktür. Hastalık özellikle genç erkeklerde daha şiddetli olarak görülürken yaş 
ilerledikçe şiddet azalmaktadır. Behçet sendromunun etiyolojisi kesin olarak 
bilinmemekle birlikte, günümüzde genetik ve çevresel fakörlerin hastalığın en 
önemli sebepleri olduğu tahmin edilmektedir. Nötrofil fonksiyonlarındaki 
bozukluklar, lemfositlerdeki değişiklikler ve bazı enfeksiyon ajanlarının da Behçet 
sendromunda rol oynadığı öne sürülmüştür. BS’nin birden fazla dokuyu ve organı 
etkileyen patolojisi ise tam olarak anlaşılamamıştır. BS ile HLA-B51 geni arasındaki 
güçlü ilişki hastalığın etiyolojisinde genetik faktörün önemini ortaya koymaktadır. 
Öte yandan özellikle monozigot ikizlerde hastalığın oluşumunda bir ilişki 
bulunmaması ve hastalık geçmişi olmayan ailelerde hastalığın az sıklıkla da olsa 
görülmesi çevresel faktörlerin önemine de dikkat çekmektedir. 
Yaşa bağlı stokastik epigenetik değişiklerin yanı sıra, özellikle hastalıklar açısından 
uyumlu olmayan tek yumurta ikizlerindeki epigenetik analizlerin hastalıklardaki 
çevreye bağlı değişikleri açıklayabileceği düşünülmektedir. 
Bu projede BS ikizlerde önemli bir metilasyon mekanizması olan globalmetilasyon 
düzenlerinin analiz edilmesi amaçlanmıştır. Bu amaçla, 4 monozigot (MZ) BS (n=8) 
ve 4 dizigot (DZ) BS ikizler (n=8), sağlıklı kontrol grubu ikizleriyle (8 ikiz, n= 16) 
karşılaştırılmıştır. Buna ek olarak biri BS olan ikizler ile, ikisi de BS olan ikizler; ve 
bir tanesi hasta olan dizigot ikizler ile sağlıklı kontrol grubu ikizleri (monozigot ve 
dizigot ikizlerden oluşan) karşılaştırılmıştır. Global metilasyon değerleri enzimlerle 
kesilmiş DNA numunelerinin HPLC (Yüksek Performanslı Likit Kromatografisi) 
kullanılarak dC ve 5-mdC dahil olmak üzere nükleozitlerin ayrılmasına 
dayanmaktadır. Elde edilen pikler altındaki alan kaydedilmiştir. Her bir numune için 
üçlü tekrar yapılmıştır (%RSD= 7%) ve bu tekrarlardan aritmetik ortalama bir değer 
elde edilmiş ve bu değerler T test ile karşılaştırılıp, analiz edilmiştir. 
Yapılan student T test istatistiksel analizlere göre, sağlıklı kontrol grubu ikizlerinin 
bireyleri arasındaki metilasyon düzenleri arasındaki farkın biri BS biri sağlıklı olan 
ikizlere göre daha düşük olduğu tespit edilmiştir (P= 0.02847). MZ BS ikizleri ile 
MZ sağlıklı ikizler arasında (P=0.04133) ve DZ BS ve DZ sağlıklı ikizler arasında 
(P=0.09551) da ayrı analizler yapılmıştır. Sonuçlar MZ ikizlerde oran ile önemli bir 
ilişkiyi işaret ederken, DZ ikizlerde bu tür bir ilişki tespit edilememiştir. Biri hasta 
olup biri sağlıklı olan MZ ve DZ ikizleri bireyleri arasnıdaki korelasyon analizi 
sonuçları DZ ikizlerde (ρ ~1) MZ ikizlere gore (ρ =0.73) daha yuksek bir 
korelasyonu işaret etmektedir. 
Bu çalışmadaki ana kısıtlayıcı etken numune sayısının az olmasıdır. Çalışmada elde 
edilen ön sonuçların doğrulanması için daha fazla veriye ihtiyaç duyulmaktadır.Bir 
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sonraki aşama bu farklılıkların gen ekpresyonu açısından etkilerinin incelenmesi 
olacaktır.  Sonuç olarak çevresel koşullar sonucu ortaya çıkan epigenetik 
farklılıklarının belirli gen bölgelerindeki etkileri de görülebilecektir. 
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1.  INTRODUCTION 
1.1 Behçet Syndrome 
 Behçet’s Syndrome (BS) is a multi-systemic inflammatory autoimmune disorder. It 
was first reported in 1937 as a syndrome with oral and genital ulceration and ocular 
inflammation (1, 2). Four major symptoms which characterize Behçet Syndrome are 
consisted of oral aphthous ulcers, ocular symptoms, skin lesions and genital 
ulcerations. Inflammation in tissues and organs throughout the body including the 
vascular system, lung, kidney and joints are probable among other BS symptoms 
(2).The diagnostic criteria have developed significantly over the decades reflecting 
the complexity and diverse demonstrations of this multi-organ systemic disease (3). 
Although BS is rare in many parts of the world, the prevalence of it is increasing in 
eastern Mediterranean countries, the Middle East, and East Asia (4). Aphthous oral 
ulcers are usually the first and most continual clinical feature of Behçet's syndrome. 
On the genitals as well, apthous ulcers appear oftentimes (e.g., the scrotum or vulva) 
(5). 
Eye involvement is the most serious manifestation of BS and affects about 50 % of 
the patients (6, 7).Inflammation of the arteries (arteritis) in patients with Behçet's 
syndrome can lead to death of the tissues whose oxygen supply depends on these 
vessels (7). Swelling, stiffness, warmth, pain, and tenderness of joints can be seen in 
patients with Behçet's syndrome who endure join inflammation (arthritis) (7). 
1.2 Genetic Epidemiology 
Genetic risk factors of BS have been investigated in several family and twins studies 
which are explained further. 
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1.2.1 Incidence of the Disease 
BS is prevalent in Middle Eastern countries with the highest rate (4 in 1000 
individuals) found in Turkey. A genetic contribution to BS is supported by the high 
sibling recurrence risk ratio, estimated from 11.4 to 52.5 in the Turkish population 
(8). 
1.2.2 Classic Genetic Studies 
Classic genetic studies of BS have been performed in family and twins studies: 
 
1.2.2.1 Family Studies 
In order to look for a possible familial aggregation of Behçet's syndrome or of its 
component features, the first-degree family members of patients with Behçet's 
syndrome were investigated (9). In a family study among Armenians, Familial 
Mediterranean Fever (FMF) has been used as a comparator disease for BS. The 
genetic load for FMF is significantly higher among the Armenians when compared to 
the load for BS among the same ethnic group. On the contrary, the rather low 
frequency of BS among the Armenians when compared to the frequency among the 
general population living in the same environment is further evidence for a genetic 
predisposition to BS. HLA- B51 does not seem to play a dominant role in the said 
predisposition (10).  
1.2.2.2 Twins Studies 
Human monozygotic (MZ) twins show different degrees of concordance for complex 
diseases, such as cancer, cardiovascular diseases, or autoimmune disorders (11). On 
the other hand concordance rates close to 100% in identical twins are used to prove 
coinheritance of mutant genes that are dominant. Most diseases or traits manifest a 
concordance in identical twins in the broad range of 5%–75% (12). Most of the twin-
based studies have focused on the concordance between siblings that has led to the 
revealing of aspect specific genes (13), although not much awareness has been paid 
to the degree of discordance, which suggests the participation of factors other than 
pure genetic changes (14).  
Genetic factors are not mentioned as absolute on their own, since only one pair of 
monozygotic twins concordant for BS has been reported (15). Genetic contribution 
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for some autoimmune diseases can be concluded due to generally higher disease 
concordance rate in monozygotic relative to dizygotic twins or other family members 
indicates (16). Nonetheless, autoimmune disease concordance in identical twins is 
incomplete most of the times, showing a requirement for additional factors, 
presumably from the environment (17). 
Case reports on MZ twins with Behçet's syndrome have been few. Frequency of MZ 
and dizygotic (DZ) twin births in BS has been sought and compared to healthy 
controls. Concordance rate among the MZ and DZ twins has also been looked in 
previous studies; the pair wise concordance rate for BS was 2/6 for MZ and 1/8 for 
DZ twins (p=0.538) (18). The frequency of MZ twin births in BS is not different than 
that in the general population while the DZ twins were seen less frequently among 
the BS patients. Genetic predisposition has been concluded according to the higher 
concordances for BS in MZ compared with DZ twins. Nevertheless, persistence of 
discordance among the MZ twins demands further research to understand non- 
genetic factors in causation of BS (18). The degree of similarity between identical 
twins brought up in the same home would indicate to the fact that all their genes are 
identical and that they share a common family environment. If identical twins can be 
located in different environment (adopted twins), the effect of environment on the 
variation among individuals can be investigated. This kind of experiments had been 
carried out for autoimmune diseases (19, 20) such as Multiple Sclerosis, but not for 
BS yet. 
1.2.3 Molecular Genetics Analyses 
The strongest marker found to be associated with BS is HLA-B51 (P= 0.00063) (1); 
in several studies, association between BS and HLA-B51 has been corroborated in 
patients of many ethnic groups; HLA-B51 and B52 were present in 63% (p<00001) 
and 21% (p<0.05), respectively, of the patients compared with 9% of the control 
group for both cases (21). The fact that HLA-B51 may play a role in the 
pathogenesis of BS, cannot confirm its utilization as a predictive value for the 
occurrence of organ involvement. Eye inflammation is exceptional in this case since 
in the presence of B51, the risk of eye involvement is superior (22). The fact that the 
disease is in association with HLA allele itself and/or some HLA-linked genes play 
in role in controlling the susceptibility to the disease according to the strong linkage 
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disequilibria (LD) observed among alleles of genes in the HLA region is yet to be 
discussed (23). 
MIC-A is also thought to be a possible additional marker of BS. The phenotype 
frequency of the MICA-TM A6 allele was significantly increased in the BS patients 
(50.0% in control subjects versus 86.8% in BS cases, P = 0.0012) (15, 24). Novel 
single nucleotide polymorphisms (SNPs) in five genes (KIAA1529, CPVL, 
LOC100129342, UBASH3B, and UBAC2) that encode proteins with both known 
and unknown functions are identified by Fei and coworkers (Odd Rations are: 2.04, 
2.26, 1.84, 1.71, and 1.61, respectively). (25). According to recent studies done by 
Gül A. et al., independent association within the MHC Class I region in BS patients 
were found. IL10 (P = 3.54 x 10
-18
) and the IL23R-IL12RB2 locus (P = 6.69 x 10
-9
) 
associations were also identified in the same study (26). In Touma Z et al. study, 
polymorphisms in the tumor necrosis factor (TNF) gene at specific locations have 
been investigated in various ethnic groups and showed probable association with BS 
(27). A familial incidence also approves genetic factors contributing to the 
development of this syndrome (28, 29). Carrying IL-1beta-511T allele (p = 0.01) 
were found to be a significant risk factors for higher periodontal scores in Turkish 
population (30). 
Transforming growth factor-beta (TGF-beta) has been shown to play a role in 
cartilage regeneration and is increased in patients with BS. Two functional 
polymorphisms of the TGF-beta pathway, TGFBR1*6A and TGFB1*CC, have also 
been found that are associated with risk of malignancy. The probable difference in 
the incidence of these polymorphisms in BS patients compared with healthy controls 
were tested and it has been concluded that lower incidence of TGFBR1*6A in BS 
patients may play a protective role against development of malignancy since BS 
cases had lower incidence of TGFBR1*6A compared with controls (11.3% versus 
13.3%, respectively) (31).  
The stimulation of Interleukin (IL) 12, IL2, Tumor Necrosis Factor α (TNF- α) exert 
strong control on the Th1/Th2 balance, which is important in the regulation of the 
inflammatory disease such as BS. TNF- α and IL10 may be regulated at the 
transcriptional level and several SNPs in the promoter regions of both genes have 
been associated with changes in expression level (32). 
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1.2.4 Environmental Effect 
Exposure to environmental factors (such as sunlight, diet, allergens, infectious agents 
or environmental toxins) in an individual with a susceptible genotype can lead to 
initiation of an autoimmune process. Critical modulating factors that can make the 
discrepancy between disease expressions include sex hormones that can act 
bilaterally with hormones of the hypothalamic-pituitary-adrenal axis (HPA) or 
sympathetic nervous system. Immune responses are affected by all these factors and 
it responses to self and foreign antigens through modulation of cytokine creation and 
effectors cell function. Outcome of the immune response is dictated by the nature of 
the antigen and the character of the immune response—that is, TH1 (T-Helper 1) or 
TH2 (T-helpe 2) (33). Human epidemiologic researches as well as increasing animal 
models show that maternal nutrition can "program" gene expression patterns in the 
embryo that remain into adulthood and impart metabolic disease (34).  
In addition to nutrition, the effect of sex hormones on appearance of complex 
diseases has been studied.  Investigating DNA and histones’ epigenetic modification 
at specific gene regulatory regions may indicate the underlying mechanisms of sex 
hormone action leading to gender differences in susceptibility to complex diseases 
such as asthma, diabetes, lupus, autism and major depression (35). 
1.3 Epigenetics 
Epigenetics refers to a heritable change in the pattern of gene expression without 
changing the primary nucleotide sequence. Functionally, an additional layer of 
transcriptional control is provided by epigenetics that plays a crucial role in normal 
physiological development, as well as in pathological conditions (27). DNA 
methylation by DNA methyltransferases (Dnmts), histone modifications such as 
methylation, acetylation, and phosphorylation, structural modifications of chromatin, 
and microRNAs as well as other noncoding regulatory RNA were epigenetic 
machanisms which happen during the full course of human life span (36). CpG 
islands -DNA hypomethylation in CpG- rich, promoter associated regions, and 
acetylated histones allow active transcription, while DNA hypermethylation and 
histone hypoacetylation elevate gene silencing (37). 
 
 
6 
1.3.1 Methylation 
Covalent modification of cytosines by addition of a methyl group to a 5' carbon of 
the cytosine ring located within CpG dinucleotides which leads to the occurrence of 
DNA methylation, is up to now the most studied epigenetic mechanism. More than 
85 % of CpG dinucleotides expanded in the genome and located in repetitive 
sequences are heavily hypermethylated/ transcription-silenced in the normal cells, a 
state critic to the integrity of the chromatin structure of the genome. The remaining 
approximately 15 % of CpG dinucleotides are clustered within the short DNA 
regions called "CpG islands", which account for 1 % of the genome. Nearly 40 to 50 
% of the genes have CpG within or around the promoters and are unmethylated in the 
normal somatic cells to a great amount (38). The methylated CpG dinucleotides 
within promoter regions can intervene with transcription factor binding; recruitment 
of methyl- CpG binding domain (MBD) proteins leads to gene expression to get 
repressed. The methylation condition of the genome is remained by three 
methyltransferases (DNMTl, DNMT3a and DNMT3b) and S-adenosyl-methionine as 
methyl donor. 
1.3.1.1 Methylation Changes 
Genetic Methylation changes are divided into two separate groups which are 
“hypomethylation” and “hypermethylation” that refer to decrease and increase in 
Cytosine and Adenosine methyl groups respectively. 
DNA is often hypomethylated in cancer at the global level. The studies of Seifert et 
al. (39) strongly support the hypothesis of early global hypomethylation in bladder 
carcinomas. Hypomethylation can result in activation of the normally silent regions 
of the genome and as a consequence, expression of repeat elements or genes that 
would normally be silent during development.  
Another class of methylation alteration is distinguished by local hypermethylation of 
individual genes, associated with aberrant gene silencing. The tissue-to-tissue 
differences exists in CpG islands methylation except with regard to the type of the 
gene methylated, also with regard to the methylation frequency of the specific gene 
and the overall methylation extent (40). 
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The researches related to global DNA methylation patterns in the neurodegenerative 
disorders have elucidated according to the following findings related to 
schizophrenia example: no difference in global genome DNA methylation of 
peripheral blood leukocytes between schizophrenia (SZ) patients and control subjects 
in addition to no association between global leukocyte DNA methylation and 
homocysteine levels was discovered, nevertheless the homocysteine levels were 
higher in SZ patients than in controls (41); on the other hand, the tendency to lower 
content of methylated deoxycytidine (mdC) of leukocyte DNA was emerged in male 
patients with SZ in comparison with controls, this shows a significant effect of age 
because this difference was more prominent in younger individuals. In females, thus 
far, no effect of age or disease status on mdC content was observed. The findings 
shows that there is a consequential sex-dependent difference in the mdC content of 
human peripheral leukocyte DNA in SZ patients (42); the decrease of methylation in 
entorhinal cortex layer II, a region displaying important Alzheimer's disease 
pathology, in which expression changes have been reported for a wide variety of 
genes, has been investigated by evaluating the immunoreativity of two markers for 
methylation and eight methylation maintenance factors (43). 
Hypermethylation of specific genes in autoimmune and other diseases was 
investigated in the following studies: heavy methylation (and histone deacetylation) 
of the FLIl gene in scleroderma fibroblasts and skin biopsy specimens shows that 
epigenetic mechanisms may take part in the fibrotic appearance of scleroderma (44); 
the killer-cell immunoglobulin-like receptor (KIR) genes expressed on natural killer 
(NK) cells - a elements of the innate immunity and the first line of defense against 
viral infections and malignancies - and on the "senescent" CD28-T cells, both 
involved in cardiovascular diseases, are suppressed by DNA methylation in most T 
cells, and DNA demethylation promotes KIR expression (45); in the same way, the 
KIR genes on the human NK cells derived from cell line NK-92MI exhibited 
epigenetic repression in consequence of the largely methylated promoter regions. 
According to Gao X. et al. study, treatment with 5-azacytidine apparently increased 
expression of KIRs, which leads to strong suppression of the NK cytolytic activity. 
This finding reveals the fact that aberrant methylation patterns of the KIR genes 
during NK-cell differentiation and maturation may have importance for their 
abnormal function (46) 
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1.3.2 Histone Modification 
Genetic Unusual changes of the activity of chromatin modifiers were investigated in 
the following studies: global histone H3/H4 hypoacetylation in active CD4+ T cells 
and global H3K9 hypomethylation in both active and inactive CD4+ T cells of 
patients with SLE when compared with the controls was investigated, but there was 
no difference among global levels of H3K4 methylation between the patients and 
controls. Additionally, the metabolic NAD-dependent protein/histone deacetylase 
(SIRTl) mRNA level was apparently raised up in active lupus CD4+ T cells in 
comparison with controls (SIRTl is an anti-aging and anti-inflammatory protein that 
regulates pro-inflammatory mediators by deacetylating histone and non-histone 
proteins). Afterwards, it was discovered that mRNA levels of CREBBP, P300, 
HDAC2, HDAC7, SUV39H2, and EZH2 were significantly down-regulated in 
patients with active lupus (47); the HDAC gene expression was fallen in CD4+ T 
cells of patients with type 1 diabetes (TlDM), which may underlie the abnormal 
immune response of CD4+ T cells resulting in destruction of the insulin-producing 
pancreatic beta cells (48); changes in trimethylation of H3K4 and to a lesser degree 
in H3K9 have been identified in the human left ventricular tissue with retained or 
damaged function, pointing out global epigenetic changes in cardiac myocytes 
associated with heart failure (49). 
Histone modifications within the specific genes were brought out in the following 
studies: a subset of epigenetically modified genes as result of a significant increase in 
genome-wide H3K9 dimethylation was found in lymphocytes, however not in 
monocytes from TlDM patients versus healthy control subjects, showing that histone 
methylation within the identified network might have effect on the etiology of TlDM 
and its complications. The analyzed genes included CLTA4, nevertheless many 
genes associated with autoimmune and inflammation-related pathways as well such 
as transforming growth factor ß, nuclear factor kB, p38 mitogen-activated protein 
kinase, toll-like receptor, and interleukin 6 (50); the active transcriptional state of the 
NFicB-p65 gene connected with the ambient or prior hyperglycaemia in diabetic 
patients and related to the phenomenon of "hyperglycaemia memory" is associated 
with remaining epigenetic marks such as enhanced methylation but not di- or 
trimethylation of H3K4 and reduced di- and trimethylation of H3K9 (51); the levels 
of SIRTl were reduced in macrophages and lungs of smokers and patients with 
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chronic obstructive pulmonary disease (COPD) because of its post-translational 
modifications by cigarette smoke-derived reactive components leading to increased 
acetylation oîRelAlp65. Thus, SIRTl plays a crucial role in the regulation of NF-kB 
dependent proinflammatory mediators in lungs of smokers and patients with COPD 
(52); acetylation of histone H4 associated with cyclooxygenase-2 (Cox-2) gene 
promoter that plays a critical role in the inflammatory response, as well as 
degradation of HDACl was induced by exposure to diesel exhaust particulate matters 
(DEP), which has been revealed to trigger pulmonary inflammation and exacerbate 
asthma and chronic obstructive pulmonary disease. DEP exposure induced 
recruitment of HAT P300 to the promoter of the Cox-2 gene, suggesting that along 
with HDAC 1 that plays a crucial role in mediating transcriptional activation of the 
Cox-2 gene, acetylation is also of importance in the regulation of its expression (53). 
Histone acetylation reflects a balance of the histone acetyltransferases and the 
histone deacetylases, and is thus vulnerable to environmental effects that alter these 
reactions, potentially altering gene expression (54). 
1.3.3 Epigenetics and Twins Studies  
MZ twins establish an excellent example of how genetically identical individuals can 
exhibit differences and as a consequence provides a unique model to study the 
contribution role of epigenetic modifications in the appearance of the phenotype. MZ 
twins share a common genotype. Nonetheless, great majority of monozygotic twin 
pairs are not identical; several types of phenotypic discordance may be emerged, 
such as differences in susceptibilities to disease and a wide range of 
anthropomorphic aspects. There are several possible explanations for these 
observations; however, one is the existence of epigenetic differences. In order to 
address this case, the global and locus-specific differences in DNA methylation and 
histone acetylation of a large cohort of monozygotic twins have been tested 
thoroughly. Although twins are epigenetically impossible to tell apart during the 
early years of life, older monozygotic twins exhibited remarkable alteration in their 
overall content and genomic distribution of 5-methylcytosine DNA and histone 
acetylation, influencing their gene-expression portrait. These findings reveal how an 
appreciation of epigenetics is missing from apprehension of how different 
phenotypes can be originated from the same genotype (55). In a study conducted by 
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Mario F. Fraga et al. in 2005, older twin pairs presented 2.5 times as many DNA 
methylation differences in the CpG islands of single-copy genes as did the younger 
twin-pairs. The RNA of the two most well-defined pairs of twins was extracted (the 
3- and 50-year-old pairs) and gene expression microarray analysis was performed 
afterwards. According to the study, from a quantitative standpoint, there were four 
times as many differentially expressed genes in the older twin pair as in the younger 
twin pair (55). In autoimmune diseases, environmentally driven epigenetic changes 
are presumed to take part in their etiology. Javierre et al. reported the first high-
throughput and candidate sequence analyses of DNA methylation to investigate 
discordance for autoimmune disease in twins. They used a cohort of MZ twins 
discordant for three diseases whose clinical signs often overlap: SLE, rheumatoid 
arthritis, and dermatomyositis. Only MZ twins discordant for SLE characterized 
widespread changes in the DNA methylation status of a significant number of genes. 
Gene ontology analysis revealed enrichment in categories associated with immune 
function. Individual analysis admitted the presence of DNA methylation and 
expression alteration in genes relevant to SLE pathogenesis. These changes happened 
in parallel with a global fall in the 5-methylcytosine content that was continuously 
accompanied with alteration in DNA methylation and expression levels of ribosomal 
RNA genes, even though no alteration in repetitive sequences were found. According 
to Javierre et.al.’s researches, not only identify potentially relevant DNA methylation 
markers for the clinical characterization of SLE patients but also support the notion 
that epigenetic changes may be critical in the clinical manifestations of autoimmune 
disease (56). 
Specific methylated cytosine residues in DNA of many eukaryotes are in interaction 
with gene regulation.  According to the recent evidences, environment–host 
interaction in some forms of autoimmunity can be seen as a consequence of the 
presence of the environmentally-induced epigenetic changes, particularly altered 
patterns of DNA methylation. A failure to maintain epigenetic homeostasis, because 
of the environmental impact, can cause abnormal gene expression in specific cells 
which leads to loss of tolerance, and the modified cells then take part to the 
manifestation of autoimmunity in genetically predisposed individuals (56). Mutations 
in genes encoding the DNA methyltransferase (DNMT) and methyl-binding proteins 
may change the pattern of gene methylation; this can result in cancer and congenital 
diseases. Modification of lysine 27 and lysine 9 of histone H3 (H3K27 and H3K9) 
 
11 
which occurs as a consequence of the alteration in the level of methyltransferase, 
correlate with changes in Rb signaling and disruption of the cell cycle in cancer cells 
(57). 
Epigenetic mechanisms determine the phenotype without changes in the genotype. 
Epigenetic information, without encoding the information, is transferred from one 
generation to the next either at the cellular level or at the level of the whole 
organism. Epigenetic mechanisms function not only at the transcriptional and post-
transcriptional level of gene activity but also at the level of protein translation and 
post-translational modifications. Cell differentiation, morphogenesis, variability and 
adaptability of an organism are processes in which they take part and may be 
affected by both genetic and environmental factors. 
Disruption of the primary epigenetic pathways can cause silencing or inappropriate 
expression of specific genes; this can lead to initiation of newly categorized 
epigenetic diseases (27). Number of human diseases which have been found to be 
associated with aberrant epigenetic regulation have risen recently (58). Previously 
unrecognized molecular signatures of disease latency, onset and progression, 
mechanisms underlying disease pathogenesis, and responses to new and evolving 
therapeutic modalities are identified and characterized by the application of 
epigenetic principles (59). For instance, many skin diseases such as common skin 
cancer result from aberrant methylation of tumour suppressor gene promoter; the 
main cause of many autoimmune diseases is known to be hypomethylation (27). 
Long-term changes in chronic disease susceptibility can be explained by epigenetic 
mechanism and the way it can be influenced by environmental factors. To look 
closer to the environmental effect on epigenetics, and as a consequence on 
development of diseases, an example can be mentioned here; prenatal under-nutrition 
or stresses may be one of two developmental pathways that may generate obesity 
causing that individuals develop with central or peripheral changes increasing their 
sensitivity to an obesogenic environment (60).  
According to Grolleau-Julius et al.’s study, epigenetic changes can explicate the 
relationship between aging and autoimmunity. The fall in immunocompetence with 
age is co-occur with the raise in the incidence of autoimmune diseases. Aging of the 
immune system, or immunosenescence, is characterized by a fall of both T and B cell 
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function, and contradictory the existance of low-grade chronic inflammation. 
Viewing evidence indicates a key role for epigenetics in human pathologies, 
including inflammatory and neoplastic disorders (37). Although some functions of 
the immune system in the eldery are reduced, others remain unchanged or even 
increased (61). A number of hypotheses have been suggested to elucidate the 
relationship between aging and the development of autoimmunity (37). An important 
characteristic of epigenetic feature is that, while they are both stable and heritable, 
they are at the same time alterable by the environment (37). 
1.4 High Performance Liquid Chromatography 
HPLC is the main method used to separate nucleosides in this study. There are 
different kinds of HPLC with specific characteristics. The method used in this 
research is Isocariotic Cation Exchange HPLC. 
1.4.1 Basic Principles of HPLC 
Classic High performance liquid chromatography is fundamentally a highly 
improved form of column chromatography. Instead of a solvent which should be 
dripped through a column under gravity, it is forced through under high pressures of 
up to 400 atmospheres; therefore HPLC is a faster method. 
One of the advantages of this method is that it allows the researcher to use a very 
much smaller particle size for the column packing material which gives a much 
greater surface area for interactions between the stationary phase and the molecules 
flowing past it. Accordingly, this allows a much better separation of the components 
of the mixture. 
There is another major improvement over column chromatography which concerns 
the detection methods that can be used. These methods are highly automated and 
extremely sensitive (62). 
1.4.2 Normal and Reverse Phase HPLC 
In normal phase HPLC, the column is filled with tiny silica particles, and the solvent 
is non-polar. A typical column has an internal diameter of 4.6 mm (and may be less 
than that), and a length of 150 to 250 mm. 
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Non-polar compounds will pass more quickly through the column since the polar 
compounds in the mixture being passed through the column will stick longer to the 
polar silica than non-polar ones will; on the other hand reverse phase HPLC uses 
non-polar stationary phase and aqueous, ands moderately polar mobile phase (62). 
1.4.3 Isocariotic Cation Exchange HPLC 
Nucleotides are positively charge in acidic solutions, enabling their separation by 
cation exchange chromatography. Among all nucleosides 5-mdC and dC have the 
highest affinity to benzenesulfonic acid-modified silica phase (64). To this end, 
isocariotic cation exchange HPLC is used to separate the nucleosides so that dC and 
5-mdC peaks appeare as the last peaks. 
 
Fig 1.1:  A flow scheme for HPLC 
 
1.4.4 Injection of the Samples 
Unlike gas chromatography pressure is involved in the injection of the sample. 
Injection of the samples is completely automated (62). 
1.4.5 Retention Time 
Retention time can be defined as the time taken for a particular compound to travel 
through the column to the detector. Calculating the time is done from the time at 
which the sample is injected to the point at which the display shows a maximum 
peak height for that compound. 
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Different compounds have different retention times. The retention time will vary for 
a particular compound depending on: 
- the pressure used (because that affects the flow rate of the solvent) 
- he nature of the stationary phase (the material it is made of and particle size)                                
- the solvent’s exact composition 
- the column temperature 
That means that conditions have to be carefully controlled retention times are being 
used as a way of identifying compounds (62). 
1.4.6 The Detector 
There are several ways of detecting when a substance has passed through the 
column. A common uses ultra-violet absorption. 
Many organic compounds absorb UV light of various wavelengths. A beam of UV 
light emits light through the stream of liquid coming out of the column, and a UV 
detector on the opposite side of the stream results in a direct reading of how much of 
the light is absorbed (62). 
The amount of light absorbed will depend on the amount of a particular compound 
that is passing through the beam at the time. 
 
 
Fig. 1.2:.UV detector of HPLC 
 
Since different compounds absorb most strongly in different parts of the UV 
spectrum, the absorbance of UV light by solvents do not interfere in the experiments. 
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Methanol, for example, absorbs at wavelengths below 205 nm, and water below 190 
nm. If methanol-water mixture is being used as the solvent, wavelength greater than 
205 nm must be used to avoid false readings from the solvent (62). 
1.4.7 Interpreting the Output from the Detector 
The output will be recorded as a series of peaks - each one representing a compound 
in the mixture passing through the detector and absorbing UV light. As long as the 
conditions on the column are under control, the retention times is being used to help 
to identify the compounds present – provided that pure samples of the various 
compounds have already been measured under those identical conditions (Standards, 
which are authentic nucleoside in this experiments) (62). 
The peaks are also used as a measure of the quantities of the compounds present. 
Here “X” is a particular compound of interest. 
If a solution containing a known amount of X gets injected into the machine, not 
only its retention time can be recorded, but it would be possible as well to relate the 
amount of X to the peak that was formed. 
The area under the peak is proportional to the amount of X which has passed the 
detector, and this area can be calculated automatically by the computer linked to the 
display. The area it would measure is shown in green in the simplified diagram 
below (62). 
 
Fig. 1.3: Simplified HPLC diagram (61) 
 
If the solution of X was less concentrated, the area under the peak would be less - 
although the retention time will still be the same. For example: 
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Fig. 1.4: Less concentration of injected compound can be interpreted by less              
area under the chromatogram (63) 
This means that it is possible to calibrate the machine so that it can be used to find 
how much of a substance is present - even in very small quantities. 
It is not possible to say anything about the relative amount of two different 
substances in the mixture (Xand Y) if UV absorption as your detection method is 
being used (62). 
 
Fig. 1.5: two different diagrams belong to two different compounds (61) 
In the diagram, the area under the peak for Y is less than that for X. That may be 
because there is less Y than X, but it could equally well be because Y absorbs UV 
light at the wavelength less than X does. There might be large quantities of Y 
present, but if it only absorbed weakly, it would only give a small peak (62). 
1.5 The Aim of the Study 
Retention In this study, it was aimed to investigate possible meaningful differences 
between methylation profile of monozygotic and dizygotic twins in which both of the 
twins are BS; additionally the same procedure were applied on the twins in whom 
one of them is healthy and the other one is BS. A final comparison was done between 
healthy control groups- with corresponding age and gender- and monozygotic and 
dizygotic twins with BS. We intended to show that difference in methylation profile 
of the individuals with the same genetic pattern (MZ twins), could be a risk factor for 
BS. Following the investigation of global methylation profile, locus specific 
methylation studies would enable us to investigate the effect of methylation pattern 
of the specific gene on the occurrence of the disease. 
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2.  MATERIAL AND METHODS 
2.1 Materials and Laboratory Equipment 
2.1.1 Used Equipments 
Lorem Appendiz A displays the equipments used in this project. 
2.1.2 Used Chemicals, Enzymes, Markers, and Buffers 
Chemicals, enzymes, and their related suppliers are given in Appendix B. Appendix 
C displays the preparation and the composition of buffers and solutions. 
2.2 Collection and Storage of Blood Samples  
Blood samples are collected from 8 Behçet syndrome twins and control group consist 
of 8 healthy twins with corresponding sex and age in CerrahpaĢa medical faculty 
Rheumatology polyclinic. Two 10 milliliter tubes were obtained from each person. A 
questionnaire, shown in Appendix D, is given to the subjects before the collection of 
the samples. According to the selection criteria, the subjects have to give their 
consent (shown in Appendix D) for the study.  Blood samples are collected in EDTA 
tubes and kept in 0C. 
2.3 DNA Isolation from Blood Samples 
The EDTA tubes contain a substance which mixes with the blood once has an anti-
coagulating effect. Before the purification step, the sample has to be incubated in 
room temperature.  
For each blood sample to be processed, 30 ml Red Blood Cell Lysis Buffer is added 
to a sterile 50 ml centrifuge tube. Centrifuge tube that will withstand a minimum of 
900 × g and accommodate a total volume of 40 ml was used. 
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10 ml mammalian blood to each tube is added. The tube was capped, and mixed 
gently by inversion. Centrifuge tube was placed on a rocking platform or gyratory 
shaker for 10 min. Tubes were Centrifuged at 875× g for 10 min.  
Carefully the clear, red supernatant was poured off and properly disposed (indicative 
of complete red cell lysis). Some residual liquid should remain with the white cell 
pellet. 
The white pellet visible at the bottom of the tube in the residual supernatant was 
vortexed thoroughly. 
5 ml White Cell Lysis Buffer was added, the tube was capped, and mixed thoroughly 
by vortexing. 
Samples were transferred to a sterile 17 × 100 mm tub. 
2.6 ml Protein Precipitation Solution was added to each sample. 
Samples were centrifuged at 12,000 × g for 10 min. 
The supernatant was poured, which contains the DNA, into a new sterile 50 ml 
centrifuge tube. Properly dispose of the protein pellet. Ethanol at this stage 
precipitates the DNA.  
3 ml cold 70% ethanol was added to the DNA pellet in the tube, and samples were 
mixed the several times by gentle inversion. Samples were centrifuged at 875 × g for 
5 minute. Supernatant was discarded afterwards.  
DNA pellet was dried by placing the sample under vacuum without heat for a few 
minutes (until the ethanol was no longer visible).  
To resuspend the DNA pellet, 1 ml TE Buffer, pH 8.0, or desired buffer was added 
and vortexed thoroughly. Samples were placed at 65°C for 30–60 min to aid in 
resuspension; samples were periodically being vortexed. 
Samples were stored in +4C. 
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2.4 Measuring DNA Amount 
The amount of nucleic acid in the purified samples was calculated with 
NANODROP spectrophotometer which is shown in table 3.1. 
2.5 Fully- Methylated DNA as a Marker for 5-mdC 
Fully methylating DNA samples is done by applying CpG methylase kit to trace the 
rise in the area below the peak which belongs to 5-mdc. 
2.5.1 CpG Methylase 
CpG Methylase (M.Sssl) kit was obtained from Zymo Research. 
CpG Methylase from Zymo Research completely methylates all cytosine residues 
( ) in double-stranded, nonmethylated and hemi-methylated DNA having the 
dinucleotide sequence 5′…CpG…3′.  The recombinant CpG Methylase is isolated 
from an E. coli strain that expresses the Methylase gene from Spiroplasma sp. strain 
MQ1.  The reaction conditions are optimized to maximize the processivity of the 
enzyme to ensure rapid, complete, and reproducible methylation of DNA for accurate 
DNA methylation analysis. This method was applied to fully methylate DNA 
samples. 
2.5.2 Methylation Setup 
The setup (below) was applied to DNA sample:  
 2 µl 10X CpG Reaction Buffer  
 1 µl 20X SAM (S-adenosylmethionine), 12 mM 
 4 µl DNA at 100-250 ng/µl  
 1 µl CpGMethylase (4 units/µl)  
 12 µl Water  
Incubate at 30 °C for 2 hours 
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In order to completely methylate all the dinucleotides, CpG methylase was added 
after 2-4 hours of initial incubation which takes 4 h to overnight. 
2.6 DNA Digestion 
DNA digestion was applied for blood samples in two steps which were explained 
further. 
2.6.1 Cutting DNA into Nucleotides 
DNA digestion is applied during two steps. During the first step, in which DNA is 
cut into nucleotides (adenine, guanine, cytosine, and thymine).1 to 10 µg of DNA 
dissolved in 43 µl of water; 0.01unit Nuclease P1 is added to DNA samples and 
incubated in 65C for 10 minutes (63); samples then was mixed with 5 µl of 10X 
digestion buffer; digestion buffer is consisted of the following chemicals: 200 mM 
acetic acid, 200 mM glycine, 50 mM MgCl2,5 mM ZnCl2, and 2 mM CaCl2to 
adjusted the pH of the buffer to 5.3.Afterwards, 1 µl of nuclease mix was added. 
Nuclease mix is consisted of 80 units DNase I (bovine pancreas) and 1.2 units RNase 
per 10 µl solution.At the end of this stage, this mixture was incubated at 37 C 
overnight (64). 
2.6.2 Converting Nucleotides to Nucleosides 
5 µl of 100 mM NaOH and 1 µl of calf intestine alkaline phosphatase (1 U/µl) were 
added. The mixture was incubated at 37 C for a further 12 to 24 h (64). 
2.6.3 Injecting Nucleosides into the HPLC Machine 
The samples which had been digested and converted into nucleotide were diluted 
with 44 µl of 12 mM HCl prior to injection and transferred into HPLC vials (64). 
2.6.4 HPLC System 
The HPLC system included SCL-10A system controller, LC-10AD liquid 
chromatograph, DGU-14A Degasser, SPD-10A UV-VIS Detector, SIL-10AD Auto 
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injector, and CTO-10A Column oven. The system was equipped with a 
NUCLEOSIL 100SA, 10 µm, 25X0.46 column.  
2.7 Mobile Phase 
The mobile phase consisted of 60 mM acetic acid dissolved in 15% acetonitrile and 
was set to pH 4.8 with NaOH. A constant flow rate was maintained at 1 ml/min, and 
UV detection was performed at 277 nm with a bandwidth of 10 nm (64, 65). 
2.8 Documentation and Interpretation 
The chromatograms were documented by software equipment connected to HPLC 
machine. All of the chromatograms were documented as original reports in which 
retention time, peaks, and the area below the dC and 5-mdC peaks were recorded. 
The amount of dC and 5-mdC were then calculated according to the calibration data 
obtained from the authentic dC and 5-mdC nucleosides peaks’ area. Calibration data 
has been shown in table 3.3 and figure 3.4 and 3.5. 
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3.  RESULTS 
3.1 DNA Isolation Results 
The DNA of BS samples were extracted by DNA Isolation Kit for Mammalian Blood 
Kit (Roche).  
In Table 3.1 measured DNA concentrations of all the samples were illustrated. 
Table 3.1 DNA concentration of the samples 
Sample 
DNA  
concentration 
 (ng/uL) Sample 
DNA  
concentration 
 (ng/uL) 
Control 
 
BS 
 C-01-1 1157.3 BS-01-1 484.7 
C-01-2 950.2 BS-01-2 559.7 
C-02-1 1386.7 BS-02-1 772 
C-02-2 573.9 BS-02-2 940.8 
C-03-1 1107.8 BS-03-1 887.6 
C-03-2 1358.4 BS-03-2 1210.9 
C-04-1 1259 BS-04-1 670 
C-04-2 622 BS-04-2 1895.7 
C-05-1 1208.7 BS-05-1 741 
C-05-2 1677.2 BS-05-2 270.6 
C-06-1 1132.2 BS-06-1 350.4 
C-06-2 443.4 BS-06-2 253 
C-07-1 514.8 BS-07-1 486.9 
C-07-2 440.2 BS-07-2 511.4 
C-08-1 736.4 BS-08-1 1064.1 
C-08-2 1488.5 BS-08-2 858.1 
 
26 
 
Measured DNA concentrations were used to determine the volume of DNA samples 
to be added to digestion mix in order to obtain the same amount of DNA for each 
HPLC injection (5 μg). 
Authentic dc and 5-mdc is used as standard for the whole experiment. Since the 
concentrations of the standard nucleosides are known, the dc and 5-mdc in the DNA 
samples of BS and controls can be traced by their retention time. 
In order to indicate dC and 5-mdC peaks in chromatograms, one of the DNA samples 
were digested and converted into nucleoside. Digested sample was injected into the 
HPLC machine and nucleoside peaks were obtained. This chromatogram was then 
compared with the chromatogram of the authentic dC and 5-mdC standards. As it is 
shown in the figures below, the retention time of the dC and 5-mdC nucleosides are 
approximately in the 7
th
 and 9
th
 minutes respectively. 
 
 
Figure 3.1: Chromatogram of digested DNA sample; peaks belong to dC and 5-mdC    
are appeared in 7
th
 and 9
th
 minute respectively 
In the figure 3.1, dC and 5-mdC peaks have been introduced to the software and the 
area below the peak has been calculated for the further studies. 
 
27 
 
Figure 3.2: Chromatogram of injected authentic dC and 5-mdC as standards. The 
exact concentration of dC and 5-mdC were calculated according to the 
area below the nucleosides of interest 
In order to confirm the retention time of 5-mdC, DNA sample were treated with 
Methylase enzyme and it is demonstrated that 5-mdC peak area was increased as 
expected.  
 
Figure 3.3: Chromatogram of digested DNA sample treated with methylase enzyme; 
fullymethylated sample confirmed the 5-mdC peak to be the last peak on 
chromatograms, which appears after dC in all the samples. 
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3.2 Behçet Syndrome Patients 
The The data of the eight Behçet Syndrome twins whose DNA samples were used in 
the study is shown in Table 3.2. 
Table 3.2 List of BS twins 
 
3.3 Calibration of dC and 5-mdC 
The The calibration was done by injecting various concentrations of dC and 5-mdC 
authentic nucleosides and calculating the area below their peak. Concentrations of 
0.2, 0.4 and 0.6 μg/mL were used to obtain the calibration curves that are 
demonstrated in Figure 3.4 and 3.5 (data shown in Table 3.3) illustrate the detected 
areas for the given concentrations of dC and 5-mdC controls. 
Since the concentation of dC and 5-mdC was in very small amounts, the selected  
concentartions to obtain the calibration curves and the equation afterwards, were in 
small amounts (0.2, 0.4, and 0.6). 
 
 
ID BS or Healthy (H) Age Gender 
M/F 
MZ/DZ 
Concordant/discordant 
BSİ-03-1 BS 46 M MZ Concordant 
BSİ-03-2 BS 46 M  
BSİ-02-1 BS 23 M MZ Concordant 
BSİ-02-2 BS 23 M  
BSİ-05-1 BS 54 M MZ Discordant 
BSİ-05-2 H 54 M  
BSİ-07-1 BS 38 M MZ Discordant 
BSİ-07-2 H 38 M  
BSİ-01-1 BS 36 M DZ Concordant 
BSİ-01-2 BS 36 M  
BSİ-06-1 BS 30 M DZ Discordant 
BSİ-06-2 H 30 M  
BSİ-04-1 BS 35 F DZ Discordant 
BSİ-04-2 H 35 F  
BSİ-08-1 BS 41 M DZ Discordant 
BSİ-08-2 H 41 M  
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Table 3.3: Area calculated for various concentrations of dC and 5-mdC 
dC   5-mdC   
Concentration  
of dC (μg/mL) Area 
Concentration  
of 5-mdC 
(μg/mL) Area 
0.2 170511 0.2 146332 
0.4 319655 0.4 324993 
0.6 467353 0.6 489954 
 
 
Figure 3.4: Calibration curve for dC nucleoside 
 
 
Figure 3.5: Calibration curve for 5-mdC nucleoside 
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The relation between the areas of the peaks and the concentration of the nucleosides 
were shown with two different equations. For the dC; y =78995x (R
2
=0.995) and for 
5-mdC; y =80935x (R
2
=0.995) which were found and used for the calculations. 
3.4 Chromatogram of BS versus Healthy Control 
Cluster Figures 3.6- 21 in APPENDIX D demonstrate the chromatograms of one of 
the repeats of the HPLC measurements (4 BS twins and 4 healthy twins (n= 16), 
representative reports for HPLC analyses). The areas obtained under the peaks were 
used to calculate the amount of dC and 5-mdC in BS twins and healthy controls. 
These values are then used to determine and compare dC: 5-mdC ratios of BS twins 
and healthy control twins. 
Data from 8 BS twins versus 8 healthy control groups were gathered and compared 
in the tables 3.4; the equations that were obtained from calibration curves of dC and 
5-mdC authentic nucleosides were used to calculate the nucleoside concentration in 
the injected samples. 
Table 3.4 demonstrates the average of the calculated ratios of 5-mdC: dC in the 
injected samples for both BS twins and healthy control twins. Injections were 
performed in triplicates and a separate ratio was calculated using the different areas 
on the chromotograms for each of them. Difference of the 5m-dC: dC ratios in-
between the twins were also indicated on the Table 3.4, and this data was used for 
statistical analysis. 
In order to highlight the difference in methylation pattern of BS and Healthy 
Controls in between twins, difference of the ratios were converted into “Fold 
Difference”. This enabled us to show the differences significantly in the charts: 
- Average area for dC and 5-mdC and 5-mdC:dC ratio in each of the samples 
(BS versus healthy) were given as figures under each peak automatically 
(Class VP software) 
- real amount of dC and 5-mdC were calculated for each of the repeats 
(Calibration equation) 
- Average of three repeats were calculated and 5-mdC: dC was obtained 
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Table 3.4: Average area for dC and 5-mdC and 5-mdC:dC ratio in each of the 
samples (BS versus healthy); data of the twins (MZ/DZ and BS/H) are 
shown in this table. Differences of the calculated ratios were given as 
well which clarifies the difference in methylation profile of the twins in 
BS twins versus Healthy controls. 
 
Sample 
CalculatedC 
Average 
Calculated 
 5-mdC 
Average 
Ratio 
 5-mdC:dC 
Average 
MZ/DZ 
BS/H 
Fold 
Differenc
e 
Difference
s of Ratios 
of Twins 
Control 
      C-01-1 0.82620 0.02638 0.0309±0.005 MZ 0.094 0.00307 
C-01-2 0.82305 0.02898 0.0340±0.004 MZ 
  C-02-1 0.73438 0.02688 0.0353±0.002 MZ 0.099 0.00336 
C-02-2 0.79630 0.02629 0.0319±0.005 MZ 
  C-03-1 0.79000 0.02906 0.0355±0.002 MZ 0.0035 0.00128 
C-03-2 0.90863 0.03468 0.0368±0.002 MZ 
  C-04-1 0.83022 0.03190 0.0370±0.002 DZ 0.63 0.00228 
C-04-2 0.78934 0.02839 0.0347±0.0008 DZ 
  C-05-1 1.29752 0.05012 0.0372±0.001 DZ 0.0052 0.00020 
C-05-2 0.79806 0.03100 0.0374±0.001 DZ 
  C-06-1 0.68084 0.02617 0.0370±0.002 MZ 0.04 0.00167 
C-06-2 2.68699 0.09845 0.0353±0.001 MZ 
  C-07-1 0.57442 0.01946 0.0328±0.002 DZ 0.044 0.00148 
C-07-2 0.70035 0.02484 0.0342±0.001 DZ 
  C-08-1 0.71521 0.03332 0.0445±0.001 DZ 0.071 0.00332 
C-08-2 0.66931 0.03362 0.0478±0.003 DZ 
  BS 
      BS-01-1 0.68491 0.02391 0.0337±0.002 DZ-BS 0.115 0.00414 
BS-01-2 0.72178 0.02841 0.0379±0.003 DZ-BS 
  BS-02-1 0.57829 0.02124 0.0354±0.002 MZ-BS 0.244 0.00987 
BS-02-2 0.82467 0.03913 0.0453±0.0003 MZ-BS 
  BS-03-1 0.79305 0.02962 0.0360±0.001 MZ-BS 0.048 0.00177 
BS-03-2 0.78959 0.03100 0.0378±0.001 MZ-BS 
  BS-04-1 0.89124 0.03267 0.0354±0.002 DZ-BS 0.053 0.00191 
BS-04-2 0.65311 0.02529 0.0373±0.001 DZ-H 
  BS-05-1 0.60788 0.02375 0.0376±0.001 MZ-BS 0.22 0.00762 
BS-05-2 0.43199 0.01335 0.0300±0.003 MZ-H 
  BS-06-1 0.67055 0.03084 0.0440±0.004 DZ-BS 0.09 0.00385 
BS-06-2 0.67936 0.02839 0.0401±0.003 DZ-H 
  BS-07-1 0.59575 0.02412 0.0390±0.0008 MZ-BS 0.09 0.00402 
BS-07-2 0.76379 0.03426 0.0430±0.005 MZ-H 
  BS-08-1 0.86000 0.03703 0.0413±0.005 DZ-BS 0.103 0.00405 
BS-08-2 0.74890 0.02896 0.0372±0.0008 DZ-H 
   
It can be seen in the Table 3.4 that the ratio of 5-mdC: dC in all the samples was 
between 0.02- 0.05, which confirms the previous studies (66). 
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Table 3.5: Three repeats of each sample, variance, and standard deviation 
 
Sample Ratio 
 5-mdC:dC 
 1 
Ratio 
 5-mdC:dC 
2 
Ratio 
 5-mdC:dC 
3 
Variance 
 for  
each 
 three  
repeat 
Ratio 
 5-mdC:dC 
Average 
Ratio 
 5-mdC:dC 
Standard 
Deviation 
Control       
C-01-1 0.028648 0.026945 0.03664 2.68E-05 0.03094 0.005176 
C-01-2 0.029424 0.035648 0.036376 1.46E-05 0.03401 0.003821 
C-02-1 0.032441 0.036131 0.036527 5.08E-06 0.03532 0.002253 
C-02-2 0.026407 0.034529 0.035326 2.44E-05 0.03196 0.004935 
C-03-1 0.032658 0.036894 0.037171 6.4E-06 0.03548 0.002529 
C-03-2 0.033931 0.038423 0.037776 5.9E-06 0.03677 0.002428 
C-04-1 0.035335 0.038528 0.037425 2.63E-06 0.037 0.001622 
C-04-2 0.033825 0.035572 0.034657 7.64E-07 0.03472 0.000874 
C-05-1 0.035568 0.038184 0.037915 2.07E-06 0.03719 0.001439 
C-05-2 0.035601 0.038235 0.037904 2.06E-06 0.03739 0.001435 
C-06-1 0.03515 0.038711 0.038038 3.58E-06 0.03702 0.001892 
C-06-2 0.034465 0.036522 0.0352 1.09E-06 0.03535 0.001042 
C-07-1 0.031324 0.03444 0.032006 2.68E-06 0.03277 0.001638 
C-07-2 0.032828 0.034861 0.035038 1.51E-06 0.03425 0.001228 
C-08-1 0.042451 0.038474 0.05623 8.68E-05 0.04451 0.009318 
C-08-2 0.045076 0.040565 0.058936 9.17E-05 0.04783 0.009574 
BS       
BS-01-1 0.031438 0.035327 0.034197 4E-06 0.03373 0.002 
BS-01-2 0.03628 0.042181 0.036526 1.11E-05 0.03787 0.003338 
BS-02-1 0.033627 0.037245 0.037106 4.2E-06 0.03543 0.00205 
BS-02-2 0.045225 0.045068 0.045591 7.2E-08 0.0453 0.000268 
BS-03-1 0.035556 0.034721 0.03724 1.65E-06 0.03601 0.001283 
BS-03-2 0.0361 0.038758 0.038864 2.45E-06 0.03778 0.001566 
BS-04-1 0.03301 0.037446 0.036589 5.54E-06 0.03537 0.002353 
BS-04-2 0.035891 0.037813 0.037998 1.36E-06 0.03728 0.001167 
BS-05-1 0.035933 0.039022 0.038154 2.54E-06 0.0376 0.00159 
BS-05-2 0.028731 0.032924 0.027804 7.44E-06 0.02998 0.002728 
BS-06-1 0.042985 0.040449 0.047681 1.35E-05 0.04397 0.003669 
BS-06-2 0.0396 0.044244 0.037619 1.16E-05 0.04012 0.0034 
BS-07-1 0.039876 0.038317 0.038603 6.88E-07 0.03891 0.00083 
BS-07-2 0.048937 0.041334 0.039327 2.57E-05 0.04293 0.00507 
BS-08-1 0.03726 0.039283 0.04829 3.45E-05 0.04128 0.005872 
BS-08-2 0.037415 0.037951 0.036355 6.6E-07 0.03723 0.000812 
 
 
33 
In Figures 3.6- 3.7, 5-mdC: dC fold differences were used to enable comparison 
between BS twins and Healthy Controls in between the twins; standard deviation for 
each of the values were shown above the related column. It can be seen that the 
values for Healthy Controls are smaller than those for BS twins which confirms the 
larger methylation pattern difference in BS twins compared to healthy controls. 
Figures 3.8- 3.10 illustrate fold differences for MZ and DZ in separate charts. A 
stronger significant relationship for MZ twins was identified compared with DZ 
twins. 
 
 
Figure 3.6: Fold difference chart for Healthy Controls 
 
 
 
Figure 3.7: Fold difference chart for MZ BS 
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Figure 3.8: Fold difference chart for MZ Healthy Controls versus BS twins (P= 
0.041) 
 
 
 
 
Figure 3.9: Fold difference chart for DZ Healthy Controls versus BS twins (P= 
0.095) 
 
In Figure 3.10 the 5-mdC: dC ratio difference among BS twins is compared with 
Healthy Controls; it is apparently illustrated that the values in BS twins group is 
larger than those in Healthy Control Groups. 
According to the Student T- test, P value for this group was obtained as 0.0288 
which indicated statistically significant relationship between BS twins and Healthy 
Controls. 
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Figure 3.10: Fold difference in Healthy Controls versus BS twins (P= 0.0288) 
3.5 Statistical Analyses 
Comparison of the twins’ parameters were done using student t-test between BS 
versus healthy twins, MZ BS twins versus MZ healthy twins, DZ BS twins versus 
DZ healthy twins, and between BS patients in which one of the twins is healthy and 
the other one is BS versus healthy twins (MZ/DZ). 
According to the student t-test analyses, it was concluded that there is a smaller 
difference between methylation pattern of the twins in healthy control group 
compared to the twins in which one of them is healthy and the other one is BS (P=  
0.02847). 
There is statistically significant difference between the ratio of 5-mdC: dC in MZ/DZ 
twins with BS (both or one of them BS) versus MZ/DZ twins in healthy controls (P= 
0.02876) assuming no significant relationship between methylation profile 
differences among twins and predisposition to BS as the null hypothesis. Another 
student analysis were done among healthy MZ and BS MZ twins and also healthy 
DZ and BS DZ twins in different groups; significant difference were found among 
MZ twins (P= 0.04133), whereas the null hypothesis could not be rejected at this 
significant level for DZ twins ( P2= 0.09551). 
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4.  CONCLUSION AND DISCUSSION 
The results obtained from this study confirm the literature on separation of 
deoxynucleosides in ten minutes under isocratic conditions. All 5 deoxynucleosides 
that are present in human DNA (Deoxyadenosine, Deoxyguanosine, Thymidine, and 
Deoxycytidine) were successfully separated using HPLC based methodology 
between 4
th
 and 10
th
 minutes. The last two peaks in the chromatograms which 
represented dC and 5-mdC enabled the global methylation patterns to be analyzed.  
The analyses that were performed on 8 BS twins and 8 healthy control twins 
demonstrated that there is a possible relation between methylation profile and the 
Behçet Syndrome. According to the student t-test findings, it is hypothesized that the 
difference between the 5-mdC: dC ratio in healthy twins is smaller than the 
difference between the 5-mdC: dC ratio in BS twins. This can lead to the conclusion 
that there might be an environmental effect which can change the epigenetic pattern 
and influence the expression of the specific genes that may be responsible for the 
appearance of the disease.  
Four separate analyses were performed on the 5-mdC: dC ratio of all the samples 
(BS versus Healthy Controls). The null hypothesis was that there is no statistically 
significant relationship between methylation profile and susceptibility to the disease. 
According to the results of three repeated HPLC analyses for each of the samples, it 
was hypothesized that the discrepancy between methylation profile (which is the 
most important feature of epigenetic pattern) between twins can be used to show the 
critical role of epigenetics on the appearance of complex diseases such as BS. It was 
thought that some factors (such as environmental effects) can influence the 
epigenetic pattern of the individuals that can lead to any change in the expression of 
specific genes. In this twins study, methylation profile of 8 BS twins (n= 16) and 8 
healthy twins (n= 16) were analyzed to look for the effect of epigenetics on the 
susceptibility of the disease. In the first group, BS twins (MZ/DZ) in which both or 
one of the twins were BS, were compared with the healthy twins (MZ/DZ); 
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calculated P value showed that there might be a meaningful relationship between the 
epigenetic discrepancies and appearance of the disease (P= 0.02876); the difference 
between 5-mdC: dC ratio of each twins in healthy groups was smaller than the 
difference between 5-mdC: dC ratio in BS twins. This results were confirmed with 
student t-test when the comparison were applied between healthy control twins 
(MZ/DZ) versus BS twins (MZ/DZ) in which only one of the twins were BS (P= 
0.02847). The latter comparison were applied to eliminate the BS twins in which 
both were BS so that to be able to investigate the role of epigenetics more 
specifically. The last two analyses were performed between BS twins (MZ) versus 
Healthy twins (MZ) in order to compare individuals with same genome. P value for 
this group of study were statistically meaningful (P= 0.04133) which lead to the 
conclusion that there might be epigenetic risk factors that can increase the 
susceptibility of BS in individual with the same genome (MZ twins); as the 
difference between twins with BS was larger than healthy twins. The last comparison 
between MZ BS twins and healthy MZ twins showed no significant relationship 
between 5-mdC: dC ratio difference and predisposition to BS (P= 0.09551). 
5-mdC: dC ratios for BS twins were more than 0.003, whereas the ratios for Healthy 
Control groups were less than 0.0035. This points out the lager difference in 
methylation pattern among BS twins once more. 
This hypothesis can be supported by the future experiments which are aimed to 
investigate the methylation profile of the specific genes which are thought to have a 
strong association with BS (HLA-B 51). To this end, findings of global methylation 
profile differences between twins in this project can be thought as a preliminary 
study for the further epigenetic researches. 
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APPENDIX A 
Laboratory Equipment 
Balances Precisa 620C SCS 
 Precisa BJ 610C 
Centrifuges Sigma 1-13 B. Braun International 
 Allegra 25R Centrifuge Beckman Coulter 
Pipettes Gilson Pipetman 20 μL 200 μl, 1000 μl 
pH meter  Mettler Toledo MP220 
Vortex HerdolphReax top 
System Contriller                                        SCL-10A
Liquid Chromatograph                              LC-10AD
Degasser DGU-14A 
UV-VIS Detector                                        SPD-10A 
Auto Injector                                              SIL-10AD
Column Oven                                             CTO-10AC 
HPLC Column                                           TEKNOKROMA- Nucleosil 100SA 
Plastic Pachaging                                       Parafilm-PECHINEY 
Heat Block                                                  Dri-Block® DB-2D- Bibby Scientific Ltd 
Serological Pipette                                     5, 10, 25 ml Greiner bio-one CELLSTAR® 
Spectrophotometer NANODROP- Thermo Scientific 
EDTA Blood Tube                                    VACUTEST- ARZERGRANDE 
Examination Gloves                                 AKO-MED 
Distilled water machine                                TKA WASSER- AUFBEREITUNGS 
Magnetic Stirrer                                        Dragon Lab  MS-H-S 
Ultrasonic Bath                                          Transsonic TP 690 
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APPENDIX B 
Chemicals 
Ethanol Riedel-de Haën 
MgCl2 Fermentas 
NaOH Riedel-de Haën 
HPLC Grade Water  Merck 
HPLC Grade Methanol                            J.T. Baker 
HPLC Grade Acetonitrile                         Merck 
Acetic Acid                                                 Riedel-de Haën 
Glysin Applichem 
Zn  Riedel-de Haën 
Ca                                                            Merck 
HCl     Merck     
Nuclease Mix (DNase bovine 
pancrease and RNase)                                         
GE Healthcare  
Alkaline Phosphatase Calf 
Intestinal (CIP) 
FINNZYMES 
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APPENDIX C 
Buffers 
Digestion Buffer 
Acetic acid                                                                                  200 mM 
Glycine 200 mM 
MgCl2    50 mM 
ZnCl2    5 mM 
CaCl2 2 mM 
adjusted with NaOH to pH 5.3 
pH to 8.0 
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APPENDIX D 
BS twins and Healthy Control Chromatograms 
 
 
 
Figure D.1: BS-01-1 dC compared with 5-mdC 
 
Figure D.2: BS-01-2 dC compared with 5-mdC 
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Figure D.3: BS-02-1 dC compared with 5-mdC 
 
Figure D.4: BS-02-2 dC compared with 5-mdC 
 
Figure D.5: BS-06-1 dC compared with 5-mdC 
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Figure D.6: BS-06-2 dC compared with 5-mdC 
 
Figure D.7: BS-07-1 dC compared with 5-mdC 
 
Figure D.8: BS-07-2 dC compared with 5-mdC 
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Figure D.9: C-01-1 dC compared with 5-mdC 
 
Figure D.10: C-01-2 dC compared with 5-mdC 
 
Figure D.11: C-02-1 dC compared with 5-mdC 
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Figure D.12: C-02-2 dC compared with 5-mdC 
 
Figure D.13: C-03-1 dC compared with 5-mdC 
 
Figure D.14: C-03-2 dC compared with 5-mdC 
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Figure D.15: C-04-1 dC compared with 5-mdC 
 
Figure D.16: C-04-2 dC compared with 5-mdC 
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APPENDIX E 
Questionnaire 
BEHÇET SENDROMLU ĠKĠZLERDE EPĠGENETĠK DEĞĠġĠKLERĠN 
ARAġTIRILMASI  ANKET FORMU 
 
Hasta / Hasta Yakını  : 
Adı- Soyadı   :     
Formun doldurulduğu tarih  : 
YaĢ    : 
Cinsiyet   : 
Ġzleyen hekim   : 
 
A) DEMOGRAFİK VERİLER 
Doğum tarihi: 
Doğum yeri: 
15 yaĢına kadar en çok yaĢadığı yer 
Medeni durumu 
Meslek 
ÇalıĢma durumu 
Sosyo ekonomik düzey 
Öğrenim düzeyi 
Toplam eğitim yılı 
 
B) ÖZ VE SOYGEÇMİŞ 
 
ÖzgeçmiĢ ( BS var/yok; baĢkahastalıkvar/yok) 
SoygeçmiĢ (Ailede BS var/yok, Ģüpheli, diğer) 
Ailede var ise kimde? 
Ailede bilinen otoimmün hastalık var/yok? (kimde) 
 
C) KLİNİK BİLGİ 
a) BaĢlangıç tarihi 
b) BaĢlangıç Ģekli 
c) Semptomlar 
d) Ġlaç /Ġlaçyanıtı/Süresi/  
 
D) LABORATUVAR BULGULAR 
a) Romatoid Faktör 
b) HsCRP 
c) HLA genotipi 
d) Diğer genetic markırlar (TNF, MICA..) 
e) DNA fingerprint  
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HASTA ve HASTA YAKINI BİLGİLENDİRME VE OLUR FORMU 
 
Bir klinik çalıĢmaya katılmak için davet edilmiĢ bulunmaktasınız. AĢağıdaki 
bilgileri okuduktan sonra çalıĢmaya katılmak isterseniz, bu formu imzalayınız. 
Formu imzalamanız çalıĢmanın kapsamı ve riskleri hakkında bilgilendirildiğinizi 
ve kararınızı serbestçe verdiğinizi belirtmektedir.  Bu rıza formunun bir kopyası 
size verilecektir. Bu formda anlamadığınız ifadeler varsa çalıĢmadaki doktorlara 
sorarak bilgi edininiz. 
  
BEHÇET SENDROMLU ĠKĠZLERDE EPĠGENETĠK DEĞĠġĠKLERĠN 
ARAġTIRILMASI  
 
Ülkemizde sık görülen Behçet sendromu, ortaya çıkma nedeni bilinmeyen, her 
çapta damarları etkileyen sistemik bir damar iltihabı hastalığıdır.  Bu çalıĢmada 
Ġstanbul Üniversitesi CerrahpaĢa Tıp Fakültesi Romatoloji Bilim Dalı ve Ġstanbul 
Teknik Üniversitesi Moleküler Biyoloji ve Genetik bölümü ortak olarak Behçet 
Hastalığı olan  ikizler ve bu bireylerle yaĢ ve cinsiyet açısından eĢleĢtirilmiĢ 
bireylerin dahil edildiği genetik bir araĢtırma yürütülmektedir. Bu kapsamda 
bireylerin genetik materyali (DNA) üzerinde yapılan incelemelerin hastalığın 
ortaya çıkma, geliĢme süreci üzerinde yatkınlığı arttıran etkenler hakkındaki 
mevcut bilgileri geliĢtirmesi hedeflenmektedir.  
 
Yukarıda gönüllü kişiye araştırmaya katılmadan önce verilmesi gereken 
bilgileri gösteren metni okudum. Bunlar hakkında bana yazılı ve sözlü 
açıklamalar yapıldı. Bu koşullarla söz konusu araştırmaya kendi rızamla, 
hiçbir baskı ve zorlama olmaksızın katılmayı kabul ediyorum. 
 
Tarih: 
 
Gönüllünün Adı-Soyadı:        
İmza:                
Adresi:  
Açıklamayı yapan araştırıcının  
Adı-Soyadı:     
İmza:       
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